vimarsana.com
Home
Live Updates
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market : vimarsana.com
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Using their SPID®-Technology, Laxxon Medical has manufactured a 3D printed oral tablet combining a GLP-1 receptor agonist and a permeation enhancer intended to increase bioavailabilityLXM.2 is being developed
Related Keywords
San Diego ,
California ,
United States ,
Alexander Ruckdaeschel ,
Helmut Kerschbaumer ,
Jessica Mchargue ,
Frances Hoggard ,
Achim Schneeberger ,
Business Development ,
Business Development Contact ,
Laxxon Medical ,
Screen Printed Innovative Drug ,
Chief Scientific ,
Advanced Patented Generics ,
Chief Strategy ,
Development Contact ,
Communications Manager ,
Ihr Portfolio ,
vimarsana.com © 2020. All Rights Reserved.